XML 50 R34.htm IDEA: XBRL DOCUMENT
v3.20.2

Collaboration, License, and Other Agreements - Sanofi, Antibody Narrative (Details) - USD ($) $ in Thousands |  | 3 Months Ended | 9 Months Ended
--- | --- | --- | ---
Apr. 01, 2020 | Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019
Disaggregation of Revenue [Line Items] |  |  |  |  |
Revenues |  | $ 2,294,000 | $ 1,743,700 | $ 6,074,200 | $ 4,694,100
Sanofi Collaboration Agreement, Antibody |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percentage of Trial Costs borne by collaborating party |  |  |  | 80.00% |
Percentage of Trial Costs borne by entity |  |  |  | 20.00% |
Levels of twelve month sales at which sales milestone payments would be received |  |  |  | $ 1,000,000 |
Period for achieving sales target for milestone payment, rolling basis |  |  |  | 12 months |
Maximum amount of sales milestone payments if total sales achieve specific levels |  |  |  | $ 200,000 |
Sanofi Collaboration Agreement, Antibody | Sales-based milestone earned |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Revenues |  | $ 50,000 | $ 0 | $ 50,000 | $ 0
Praluent Agreement |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Royalty percentage to be received on net product sales outside of the United States | 5.00% |  |  |  |
Percentage of damages company is responsible for | 50.00% |  |  |  |
Sanofi | Praluent Agreement |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percentage of royalty payment that can be used to offset litigation proceedings | 50.00% |  |  |  |

X
- Definition Aggregate amount of twelve month sales upon which sales milestone would be received. + References No definition available. + Details
Name: | regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived
Namespace Prefix: | regn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Loss Contingency, Percentage Of Damages Responsible For + References No definition available. + Details
Name: | regn_LossContingencyPercentageOfDamagesResponsibleFor
Namespace Prefix: | regn_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The maximum amount of sales milestone payments the Company is eligible to receive when and if total annual sales achieve certain specified levels. + References No definition available. + Details
Name: | regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels
Namespace Prefix: | regn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage Of Royalty Payment That Can Be Offset + References No definition available. + Details
Name: | regn_PercentageOfRoyaltyPaymentThatCanBeOffset
Namespace Prefix: | regn_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of subsequent Shared Phase 3 Trial costs borne by the collaborating party upon receipt of the first positive Phase 3 trial results for a co-developed drug candidate. + References No definition available. + Details
Name: | regn_PercentageOfTrialCostsBorneByCollaboratingParty
Namespace Prefix: | regn_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of subsequent Shared Phase 3 Trial costs borne by the Company upon receipt of the first positive Phase 3 trial results for a co-developed drug candidate. + References No definition available. + Details
Name: | regn_PercentageOfTrialCostsBorneByEntity
Namespace Prefix: | regn_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period for Achieving Sales Target for Milestone Payment, Rolling Basis + References No definition available. + Details
Name: | regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis
Namespace Prefix: | regn_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty Percentage To Be Received On Net Product Sales Outside Of United States + References No definition available. + Details
Name: | regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates
Namespace Prefix: | regn_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=regn_SalesBasedMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_PraluentCrossLicenseAndCommercializationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=regn_SanofiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |